← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Lpath Therapeutics, Inc.
San Diego, CA
$10,172,009
Total funding
12
Grants
Funding over time
peak $4M · FY2005–14$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$10,172,009 · 12
By mechanism
R44$5,749,472 · 3
RC3$3,000,000 · 1
R43$1,422,537 · 8
Investigators at Lpath Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Commercialization of iSONEP, a Humanized Monoclonal Antibody Against the Bioactiv$3,000,000
RC3 · FY2010 · EY
Sphingomab Mitigates the Multiple Pathologies of Age-Related Macular Degeneration$1,418,276
R44 · FY2008 · EY
Commercialization of ASONEP for the Treatment of Cancer$1,000,000
R44 · FY2009 · CA
Commercialization of ASONEP for the Treatment of Cancer$1,000,000
R44 · FY2011 · CA
Commercialization of ASONEP for the Treatment of Cancer$1,000,000
R44 · FY2010 · CA
Anti-sphingolipid antibodies for the treatment of cancer$832,672
R44 · FY2005 · CA
THERAPEUTIC APPROACH TO SULFUR MUSTARD EXPOSURE$399,709
R43 · FY2004 · AI
Anti-sphingolipid antibodies for the treatment of cancer$274,536
R44 · FY2006 · CA
Novel Anti-LPA Antibody for the Treatment of Traumatic Brain Injury$223,988
R44 · FY2014 · NS
Anti-sphingolipid antibodies for the treatment of cancer$155,353
R43 · FY2004 · CA
Structure Based Design of Humanized Monoclonal Antibodies that Recognize Bioactiv$152,724
R43 · FY2009 · GM
Role of Sphingolipids in Cardiac Ischemia$152,553
R43 · FY2004 · HL
Sphingolipids as Markers of Cardiac Ischemia$151,601
R43 · FY2004 · HL
Novel Anti-LPA Antibody for the Treatment od Diabetic Neuropathy$145,230
R43 · FY2013 · DK
Development of therapeutic monoclonal antibody to the bioactive lipid lysophospha$139,523
R43 · FY2009 · CA
Sphingomab Mitigates the Multiple Pathologies of Age-Related Macular Degeneration$125,844
R43 · FY2007 · EY